Non-Hodgkin Lymphoma   

Would you prefer certain modalities if using the lower dose?   This question is part of our collaboration with ASTRO 2025 to highlight impactfu...

Should the reduced dose be adopted for all, or would you reserve this approach for specific patient subgroups?   This question is part of our c...

Are there other mutations/biomarkers in CLL which may specifically predict for response or resistance to pirtobrutinib?

In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? ...

Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with p...

Is the data sufficient to change your practice?

Does cumulative exposure to BTKi increase potential risk of cardiac toxicity?

Should pirtobrutinib be viewed as a bridge to CAR-T or transplant or a destination therapy?

How do you predict which patients may be in a high risk group and less likely to benefit from a second BTKi?

NCCN guideline V4.2021 DLBCL page BCEL-3 states stage I-II, bulky >= 7.5cm should be treated with 6 cycles of RCHOP, but most bone lymphoma studies...

Do you prefer a cHL chemotherapy backbone or PMBL chemotherapy backbone?

What if the patient has a history of confirmed COVID-19 but has since recovered?